AstraZeneca Rating Reiterated by JPMorgan Chase & Co. (AZN)
AstraZeneca (LON:AZN)‘s stock had its “neutral” rating reaffirmed by JPMorgan Chase & Co. in a research note issued on Tuesday, American Banking News.com reports. They currently have a GBX 3,700 ($60.97) price objective on the stock. JPMorgan Chase & Co.’s target price would suggest a potential downside of 4.27% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Friday. They now have a GBX 3,600 ($59.32) price target on the stock. Separately, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of AstraZeneca in a research note to investors on Tuesday, January 21st. They now have a GBX 3,112 ($51.28) price target on the stock. Finally, analysts at Swedbank reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Monday, January 20th. They now have a GBX 3,378.87 ($55.67) price target on the stock. Twelve research analysts have rated the stock with a sell rating, fifteen have given a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 3,360.66 ($55.37).
Shares of AstraZeneca (LON:AZN) traded up 0.25% on Tuesday, hitting GBX 3865.0002. 3,014,463 shares of the company’s stock traded hands. AstraZeneca has a 52-week low of GBX 2895.00 and a 52-week high of GBX 3964.50. The stock has a 50-day moving average of GBX 3660.31 and a 200-day moving average of GBX 3363.. The company’s market cap is £48.428 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.